long intergenic non-protein coding RNA 2049Genealiases: []
Q-omics provides the consensus-scored LINC02049 profile across patient tissues and cancer cell-line models. LINC02049 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LINC02049 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, LINC02049 RNA expression shows 8,117 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight LIHC, LUSC, and COAD as cancer lineages where LINC02049 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02049 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02049 survival associations across molecular data types. LINC02049 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02049 RNA expression–survival associations across cancer types. High LINC02049 expression shows unfavorable associations in LIHC, KIRC, STAD, UCEC and SARC, but favorable associations in LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for LINC02049 RNA expression.
This table summarizes LINC02049 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02049. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02049 shows lower tumor expression in THCA and higher tumor expression in LUSC. The LUSC box plot shows higher LINC02049 RNA expression in tumor versus normal tissue (log2 FC = +0.023, t-test p = .021).
This table shows molecular features associated with LINC02049 in patient tissues and cancer cell lines. In patient samples, LINC02049 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
